LivingGLP1
Study S000577

More Than Weight Loss: Real-World Tirzepatide Use in Post-Bariatric Weight Regain and Preoperative Obesity Care

ClinicalTrials.gov record

Registration

Registration
NCT07382180
Acronym
TIR-REAL
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
254
Start
2025-02-01
Primary completion
2026-01-18
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Conditions
Obesity & Overweight; Weight Regain; Obesity, Morbid
Interventions
DRUG:Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Percentage Total Body Weight Loss (%TBWL) [From baseline (initiation of tirzepatide therapy) to 6 months of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.